Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Baldwin Investment Management LLC

Baldwin Investment Management LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,879 shares of the medical research company's stock after buying an additional 1,119 shares during the period. Thermo Fisher Scientific accounts for about 0.6% of Baldwin Investment Management LLC's portfolio, making the stock its 23rd largest holding. Baldwin Investment Management LLC's holdings in Thermo Fisher Scientific were worth $4,619,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Banque Transatlantique SA purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $79,041,000. Banque de Luxembourg S.A. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $442,000. Bellevue Group AG boosted its position in shares of Thermo Fisher Scientific by 13.7% during the 4th quarter. Bellevue Group AG now owns 60,962 shares of the medical research company's stock valued at $31,714,000 after acquiring an additional 7,339 shares during the last quarter. Bearing Point Capital LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $254,000. Finally, Benjamin Edwards Inc. raised its position in shares of Thermo Fisher Scientific by 2.0% during the 4th quarter. Benjamin Edwards Inc. now owns 14,372 shares of the medical research company's stock valued at $7,478,000 after buying an additional 284 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,075 shares of company stock valued at $7,305,942. Corporate insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TMO shares. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Royal Bank of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Scotiabank dropped their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Finally, Robert W. Baird decreased their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $607.43.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $0.77 during trading on Wednesday, hitting $407.79. 2,959,388 shares of the company were exchanged, compared to its average volume of 1,788,786. The firm's fifty day moving average price is $471.62 and its 200 day moving average price is $518.58. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $153.94 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $403.51 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm's quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company posted $5.11 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.